DOJ Backs AbbVie At 7th Circ. In 'Patent Thicket' Case

Law360 (January 4, 2021, 6:33 PM EST) -- The U.S. Department of Justice has thrown its weight behind AbbVie at the Seventh Circuit as Humira buyers look to revive their suit accusing the drugmaker of employing a "patent thicket" and other tactics to insulate its blockbuster immunosuppressant from competition.

The DOJ's antitrust division filed an amicus brief on Dec. 28 attacking the buyers' allegations that AbbVie illegally maintained its monopoly position, in part by amassing hundreds of patents covering the drug. The brief contended that such a theory would make it an antitrust violation for companies to secure large patent portfolios, "a result contrary to antitrust law and patent...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!